返回主頁 >>   
                             
 

?BRC1502 - 乳腺癌組織芯片

?
批號 芯粒 大小 厚度 排列 質檢/質控 價格 下載
?BRC1502 150 1.1mm 4um 10X15 H&E, IHC 抗纖維蛋白/細胞角蛋白 查詢 PDF文件
訂購: [email protected]                         電話: 0773-3119018
?
適用于:免疫組化或原位雜交對蛋白或RNA分子在多種乳腺癌組織與正常、炎癥等組織表達差異性分析。

描述:150芯,包括70例不同類型乳腺癌(70例病例完全不同于BRC1501),5例正常及炎癥等組織,雙芯布陣。組織經10%中性福爾馬林緩沖液固定24小時,用統一標準的方法加工。組織芯片被固定于美國進口的Superfrost Plus 或APES處理的Superfrost 防脫載玻片上。在4°C保存。從發貨日開始所有芯片均有6個月的保質期。每片芯片的完整率大于>90%。
?
?

芯粒位置

年齡

性別

病理描述

分級

?TNM分期

AR

ER

PR

HER2

A1,B1

47

正常/增生

 

 

+, 2%

++, 10%

++~+++, 10%

-

A2,B2

40

正常/增生

 

 

+, 2%

+~++, 5%

++, 10%

-

A3,B3

42

正常/增生

 

 

-

+~++, 10%

++, 2%

-

A4,B4

16

纖維腺瘤

 

 

+, 5%

++~+++, 50%

++~+++, 50%

-

A5,B5

50

纖維腺瘤

 

 

++, 5%

+++, 5%

+++, 10%

+

A6,B6

35

浸潤性小葉癌

II~III

T4N0M0

++~+++, 60%

+++, 90%

+~++, 30%

-

A7,B7

40

浸潤性導管癌

III

T3N0M0

-

-

-

+++

A8,B8

53

浸潤性小葉癌

I

T3N0M0

++, 2%

-

-

+++

A9,B9

45

浸潤性導管癌

I~II

T3N0M0

++, 5%

+++, 80%

+++, 70%

+~++

A10,B10

56

浸潤性導管癌

II~III

T2N0M0

++, 10%

+++, 100%

++, 5%

+++

A11,B11

33

浸潤性導管癌

II~III

T2N0M0

-

+, 10%

-

+-

A12,B12

37

浸潤性小葉癌

II~III

T3N2M0

-

+++, 50%

++, 20%

+

A13,B13

50

浸潤性導管癌

II

T3N0M0

-

-

-

++~+++

A14,B14

64

浸潤性小葉癌

II~III

T4N1M0

+, 5%

+++, 80%

+, 20%

-

A15,B15

44

浸潤性導管癌

II~III

T3N1M0

++~+++, 50%

+~++, 10%

-

+++

C1,D1

55

浸潤性導管癌

II~III

T2N1M0

-

+, 5%

-

+++

C2,D2

47

浸潤性導管癌

II~III

T2N0M0

-

-

-

+++

C3,D3

50

浸潤性導管癌

II~III

T2N1M0

++, 5%

+++, 60%

+++, 50%

+

C4,D4

51

浸潤性導管癌

II~III

T4N3Mx

-

++~+++, 50%

+, 10%

-

C5,D5

36

浸潤性導管癌

II

T3N1M0

-

-

-

-

C6,D6

66

浸潤性導管癌

II~III

T2N0M0

++, 5%

+++, 80%

+, 5%

+-

C7,D7

50

浸潤性導管癌

II~III

T2N0M0

++, 10%

+++, 80%

++, 20%

-

C8,D8

66

浸潤性導管癌

III

T2N1M0

+, 5%

+++, 80%

-

-

C9,D9

61

浸潤性乳頭狀癌

I~II

T3N0M0

++, 20%

+++, 60%

+++, 50%

+~++

C10,D10

57

浸潤性導管癌

II~III

T2N1M0

-

+++, 100%

++, 5%

+-

C11,D11

60

浸潤性導管癌

II~III

T2N0M0

-

++~+++, 60%

-

-

C12,D12

56

肉瘤

 

T2N0M0

-

-

-

-

C13,D13

33

導管原位癌

I

TisN0M0

-

-

-

+++

C14,D14

40

浸潤性導管癌

II

T4N2Mx

+, 5%

+, 5%

++~+++, 60%

+++

C15,D15

34

導管原位癌

I

TisN0M0

-

-

-

+++

E1,F1

40

浸潤性導管癌

II

T2N0M0

+, 5%

-

-

+++

E2,F2

50

浸潤性導管癌

II~III

T2N0M0

+, 5%

-

-

+++

E3,F3

44

浸潤性導管癌

II

T2N0M0

-

-

-

-

E4,F4

58

浸潤性導管癌

II

T2N0M0

-

++~+++, 50%

+, 2%

+-

E5,F5

37

浸潤性導管癌

III

T4N1M0

-

-

-

-

E6,F6

61

浸潤性導管癌

II~III

T4N0M0

+, 2%

+++, 60%

++, 20%

+

E7,F7

41

浸潤性導管癌

I

T2N0M0

+, 2%

-

-

+++

E8,F8

28

浸潤性導管癌

II

T2N0M0

+, 5%

+++, 80%

-

+

E9,F9

30

浸潤性導管癌

II~III

T2N2M0

+, 5%

+, 30%

++, 10%

+++

E10,F10

52

浸潤性導管癌

III

T2N0M0

-

-

-

-

E11,F11

48

浸潤性導管癌

III

T2N0M0

-

+++, 80%

+, 5%

-

E12,F12

43

浸潤性導管癌

II

T2N2M0

+, 5%

++, 30%

-

+++

E13,F13

46

浸潤性導管癌

II~III

T2N0M0

-

-

-

++

E14,F14

68

浸潤性乳頭狀癌

I~II

T2N0M0

+~++, 50%

+++, 100%

+++, 80%

+

E15,F15

49

浸潤性導管癌

II~III

T2N0M0

-

-

-

-

G1,H1

51

浸潤性導管癌

II~III

T2N0M0

-

+, 10%

+~++, 5%

+++

G2,H2

45

浸潤性導管癌

II~III

T2N0M0

+, 5%

+++, 80%

-

+

G3,H3

30

浸潤性導管癌

III

T2N0M0

++~+++, 20%

++~+++, 80%

+++, 60%

-

G4,H4

54

浸潤性導管癌

II

T2N0M0

++~+++, 30%

-

-

-

G5,H5

60

浸潤性導管癌

II

T2N0M0

+, 2%

+++, 90%

+, 10%

-

G6,H6

44

浸潤性小葉癌

II~III

T2N0M0

-

+, 60%

+++, 80%

-

G7,H7

38

浸潤性導管癌

II~III

T2N2M0

-

++~+++, 80%

-

+-

G8,H8

43

浸潤性導管癌

II

T2N0M0

-

++, 60%

-

-

G9,H9

42

浸潤性導管癌

II~III

T2N0M0

+, 5%

+~++, 50%

++, 60%

+

G10,H10

55

浸潤性導管癌

II

T2N0M0

-

-

-

+++

G11,H11

49

浸潤性導管癌

II~III

T2N0M0

++~+++, 80%

+++, 100%

+~++, 20%

+

G12,H12

41

浸潤性導管癌

I~II

T3N0M0

-

-

-

+++

G13,H13

41

粘液癌

II

T3N0M0

+, 5%

++, 50%

++~+++, 15%

+

G14,H14

41

浸潤性導管癌

II~III

T2N0M0

-

-

-

+++

G15,H15

46

浸潤性導管癌

II~III

T4N0M0

-

++, 50%

-

-

I1,J1

68

浸潤性導管癌

II~III

T4N0M0

-

+++, 80%

++~+++, 20%

-

I2,J2

49

浸潤性導管癌

II~III

T2N0M0

+, 2%

++~+++, 80%

-

+

I3,J3

55

浸潤性導管癌

II

T2N0M0

+, 5%

+++, 100%

++~+++, 50%

-

I4,J4

44

浸潤性導管癌

II~III

T4N3Mx

-

-

-

+++

I5,J5

60

浸潤性導管癌

II

T2N0M0

-

-

-

+++

I6,J6

43

浸潤性導管癌

I~II

T3N0M0

+, 5%

++~+++, 60%

+++, 60%

-

I7,J7

44

浸潤性導管癌

II~III

T3N0M0

+, 2%

++~+++, 80%

++~+++, 50%

-

I8,J8

42

浸潤性導管癌

II~III

T4N2M0

+, 5%

++~+++, 60%

+~++, 20%

-

I9,J9

41

浸潤性導管癌

II~III

T3N0M0

+, 2%

+, 20%

++, 50%

-

I10,J10

56

浸潤性導管癌

II~III

T2N0M0

-

++~+++, 60%

+, 10%

-

I11,J11

79

浸潤性導管癌

II

T2N0M0

+, 20%

-

-

-

I12,J12

57

浸潤性導管癌

II

T3N0M0

+, 5%

-

-

+++

I13,J13

54

浸潤性小葉癌

III

T4N3M1

-

+++, 80%

-

-

I14,J14

33

浸潤性導管癌

II

T4N2M0

-

-

-

++~+++

I15,J15

42

浸潤性導管癌

II~III

T2N0M0

+~++, 5%

+,10%

+~++, 5%

++

?
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
所有產品 | 聯系我們 | 版權聲明
版權所有 ? 桂林泛譜生物技術有限公司 桂林市高新區留學人員創業園B座202室 541004
体彩天津11选5走势图